Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Medical management of patients with an acute stroke: treatment and prevention Alberts MJTop Stroke Rehabil 2003[Fal]; 10 (3): 34-45Stroke is a common and serious disorder and will probably occur with increasing frequency due to an aging of the population. Acute therapies aimed at reversing the effects of acute ischemic stroke are limited to recombinant tissue plasminogen activator administered intravenously within 3 hours of stroke onset. Neuroprotective agents and acute anticoagulation with agents such as heparinoids and heparin are not effective in most cases. Poststroke medical complications such as infection and venous thromboembolism are common but are largely preventable. A variety of medical therapies such as antiplatelet agents, warfarin, statins, and ACE inhibitors can reduce the risk of a recurrent stroke. A key aspect of management for stroke is selection of the proper treatment regimen for each patient.|Acute Disease[MESH]|Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH]|Anticoagulants/*therapeutic use[MESH]|Brain Ischemia/physiopathology[MESH]|Fibrinolytic Agents/*therapeutic use[MESH]|Humans[MESH]|Infections/etiology[MESH]|Recurrence[MESH]|Stroke/*complications/*prevention & control/therapy[MESH]|Thromboembolism/etiology/prevention & control[MESH]|Tissue Plasminogen Activator/*therapeutic use[MESH] |
